Ventricular Tachycardia
Conditions
Brief summary
This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular tachycardia in whom ventricular tachycardia recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or desired.
Detailed description
This is a regulated, prospective, multi-center trial designed to evaluate the safety and effectiveness of the FlexAbility\[TM\] Ablation Catheter, Sensor Enabled\[TM\] (FlexAbility SE) catheter to obtain an indication to treat monomorphic ventricular tachycardia (MMVT) in the United States of America (US). The clinical trial has two cohorts: one is a randomized ischemic cardiomyopathy (ICM) cohort and the second is a concurrent single-arm non-ischemic cardiomyopathy (NICM) cohort. Four hundred ten (410) subjects with drug refractory sustained MMVT and ICM and 182 subjects with drug refractory sustained MMVT and NICM will be enrolled at up to 35 centers worldwide. Study subjects who have drug refractory sustained MMVT and ICM will be randomized 1:1 to treatment with the FlexAbility SE catheter ablation system in the Treatment group, or the ThermoCool, ThermoCool NaviStar, or ThermoCool SmartTouch Ablation Catheter from Biosense Webster in the Control group. Since at study start there was no approved device for VT ablation in patients with NICM to use as a comparator, subjects who have drug refractory MMVT and NICM will be treated with the FlexAbility SE catheter ablation system only.
Interventions
DEVICEMarket Approved RF Ablation System
Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
Subjects receive ablation treatment using an ablation system that is not FDA approved.
Sponsors
Abbott Medical Devices
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Subjects are blinded to the randomization assignment.
Intervention model description
Pivotal medical device study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Structural heart disease (ischemic or non-ischemic) with one of the following: * Confirmed diagnosis via echocardiography and/or cardiac CT/MRI \[computed tomography/magnetic resonance imaging\], or * Left ventricular ejection fraction (EF) \<40% (documented within the last 6 months via echocardiography, or * Arrhythmogenic RV \[right ventricular\] cardiomyopathy/dysplasia (per 2010 ARVC/D \[arrhythmogenic right ventricular cardiomyopathy/dysplasia\] Task Force Criteria).27 * At least one documented episode of sustained MMVT by either EGM \[cardiac electrogram\] or ECG \[electrocardiogram\] in the 6 months prior to enrollment * Implanted with a market released ICD \[implantable cardioverter-defibrillator\] or CRT-D \[cardiac resynchronization therapy-defibrillator\] for at least 30 days prior to index ablation procedure * Refractory (i.e. not effective, not tolerated or not desired) to at least one anti-arrhythmic medication (either amiodarone or sotalol) for treatment of MMVT * At least 18 years of age * Informed of the nature of the study, agreed to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical study site. * Able and willing to comply with all study requirements
Exclusion criteria
* Implanted with a subcutaneous ICD * Implanted with a ventricular assist device (VAD) (e.g. TandemHeart) * Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO) * Presence of intracardiac thrombus verified via computer tomography (CT), magnetic resonance imaging (MRI), transesophageal echocardiogram (TEE), or transthoracic echocardiogram (TTE) within 48 hours prior to the index ablation procedure or intra-procedure intracardiac echocardiography (ICE) o For subjects with a history of AF \[atrial fibrillation\], this verification must be done via TEE or ICE * ST elevation myocardial infarction (MI) within 60 days prior to index ablation procedure * Previous cardiac surgery (e.g. ventriculotomy, atriotomy, coronary artery bypass graft), within 60 days prior to index ablation procedure * Percutaneous coronary intervention (PCI) within 30 days prior to index ablation procedure * Idiopathic VT * Incessant VT (continuous sustained VT that promptly recurs despite repeated intervention for termination over ≥3 hours) necessitating immediate treatment or requiring hemodynamic support prior to the ablation procedure * VT/VF \[ventricular tachycardia/ventricular fibrillation\] thought to be from channelopathies * Reversible cause of VT * Severe aortic stenosis or flail mitral valve * Mechanical mitral and aortic valve * History of stroke with modified Rankin scale \> 3 (See Appendix C) * Unstable angina * Chronic NYHA \[New York Heart Association\] Class IV heart failure * Ejection fraction \< 15% * Thrombocytopenia (defined as platelet count \<80,000) or coagulopathy * Contraindication to systemic anticoagulation (i.e. heparin, warfarin, or a direct thrombin inhibitor) * Women who are pregnant or nursing * Active uncontrolled infection * Other anatomic or co morbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow up requirements, or impact the scientific soundness of the study results * Enrolled in an investigational study evaluating another device or drug that would confound the results of this study * Have a life expectancy of less than 12 months due to any condition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of complications | 7 days | The primary safety endpoint is a composite of cardiovascular-related and procedure-related major complications through 7 days post index ablation procedure. |
| Freedom from recurrence of VT | 6 months | The primary effectiveness endpoint is freedom from recurrent sustained MMVT at 6 months and a new or increased dose Class I or III antiarrhythmic drugs (AAD) at 6 months following the index ablation procedure. |
Countries
Australia, Czechia, France, Germany, Italy, Spain, United Kingdom, United States
Outcome results
None listed